Lyra Therapeutics, Inc. (LYRA)

US — Healthcare Sector
Peers: CTMX  ASMB  ACHL  NLTX  TIL  NXTC  SPRO  NUVB  CGEM  BOLT  DAWN  AUTL 

Automate Your Wheel Strategy on LYRA

With Tiblio's Option Bot, you can configure your own wheel strategy including LYRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LYRA
  • Rev/Share 0.018
  • Book/Share 0.0589
  • PB 83.7258
  • Debt/Equity 8.6147
  • CurrentRatio 2.956
  • ROIC -1.6642

 

  • MktCap 6533926.0
  • FreeCF/Share -0.8605
  • PFCF -0.1155
  • PE -4.0763
  • Debt/Assets 0.5923
  • DivYield 0
  • ROE -4.7437

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
LYRA
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company's lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.

Read More
image for news Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
LYRA
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.

Read More
image for news Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates

About Lyra Therapeutics, Inc. (LYRA)

  • IPO Date 2020-05-01
  • Website https://lyratherapeutics.com
  • Industry Biotechnology
  • CEO Dr. Maria Palasis Ph.D.
  • Employees 30
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.